Sector: MedicalEndo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP)
Ranking History
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 168 |
Technical : | 230 |
Performance : | 196 |
Overall: | 246 |
Number of Stocks: | 306 |
Scan Date: | 10/20/2009 |
Sector: | Medical |
Funamental : | 170 |
Technical : | 241 |
Performance : | 196 |
Overall: | 248 |
Number of Stocks: | 305 |
Scan Date: | 10/15/2009 |
Sector: | Medical |
Funamental : | 171 |
Technical : | 235 |
Performance : | 191 |
Overall: | 242 |
Number of Stocks: | 305 |
Headlines
- Bioniche communique ses résultats pour le premier trimestre de 2010 et annonce l'atteinte d'une première étape dans le cadre d'une entente de licence
Nov 06, 2009 02:29 PM | ENDP
- RXi Pharmaceuticals Appoints Noah D. Beerman as CEO
Nov 06, 2009 07:15 AM | ENDP
- Bioniche Reports Fiscal 2010 First Quarter Results And Achievement of First Milestone Under Licensing Agreement
Nov 06, 2009 07:01 AM | ENDP
- Partnerships in Clinical Trials Expands Its Global Reach
Nov 02, 2009 10:56 AM | ENDP
- Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
Oct 29, 2009 07:15 AM | ENDP
- Presentation of Verilogue Data at Upcoming Eye for Pharma Conference Reveals How to Identify and Overcome Patient Adherence Challenges
Oct 21, 2009 09:00 AM | ENDP
- Endo Pharmaceuticals Gives Update on Regulatory Status of FORTESTA(TM)
Oct 19, 2009 08:31 AM | ENDP
- Endo Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29, 2009
Oct 08, 2009 09:03 AM | ENDP
- Pennsylvania Bio Adds Two New Members to Its Board of Directors
Oct 07, 2009 02:27 PM | ENDP, FRX
- Endo Pharmaceuticals Announces Expiration of Cash Tender Offer for Ledgemont PhaRMA(SM) Secured 16% Notes
Sep 25, 2009 09:03 AM | ENDP
- Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
Aug 12, 2009 08:31 AM | ENDP
- Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
Jul 30, 2009 10:51 AM | ENDP, NVS
- Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
Jul 30, 2009 07:53 AM | ENDP, NVS
- BenchmarkJournal.Com Free Analyst Review for QLGC, NEXM, GERN, ENDP, LOGI and ALXN
Jul 21, 2009 10:23 AM | ALXN, ENDP, GERN, LOGI, NEXM, QLGC
- Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
Jul 10, 2009 08:01 AM | ENDP
- Bioniche Life Sciences Inc. and Endo Pharmaceuticals Inc. Sign Licensing Agreement for Urocidin(TM)
Jul 10, 2009 08:00 AM | ENDP
- Endo Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009
Jul 01, 2009 04:52 PM | ENDP
- Men with Low Testosterone See Multiple Doctors Before Being Diagnosed; Many Dissatisfied with Current Treatment Options
Jun 10, 2009 08:31 AM | ENDP
- Penwest and Endo Grant Valeant Pharmaceuticals Exclusive License to Market Opana(r) ER in Canada, Australia and New Zealand
Jun 09, 2009 07:31 AM | ENDP, PPCO, VRX
- Endo Pharmaceuticals to Present at Goldman Sachs 30th Annual Healthcare Conference
Jun 05, 2009 04:30 PM | ENDP
- Form 4 Scodari Joseph C For: Sep 30 (10K)
Oct 01, 2009 08:34 PM
- Form 4 MONTAGUE WILLIAM P For: Sep 30 (10K)
Oct 01, 2009 08:33 PM
- Form 4 Spengler William For: Sep 30 (10K)
Oct 01, 2009 08:30 PM
- Form 4 Holveck David For: Sep 01 (10K)
Sep 04, 2009 10:07 AM
- Form 4 LEVIN ALAN G For: Jul 28 (10K)
Jul 29, 2009 07:34 PM
- Form 4 MONTAGUE WILLIAM P For: Jun 30 (10K)
Jul 01, 2009 07:57 PM
- Form 4 Scodari Joseph C For: Jun 30 (10K)
Jul 01, 2009 07:56 PM
- Form 4 Spengler William For: Jun 30 (10K)
Jul 01, 2009 07:55 PM
- Form 3 LEVIN ALAN G For: Jun 01 (10K)
Jun 04, 2009 06:56 PM
- Form 4 Spengler William For: Mar 31 (10K)
Mar 31, 2009 10:19 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
ENDP
|
Compare to S&P
|
| YTD |
-13.45 %
|
-24.55 %
|
| 4 Weeks |
1.31 %
|
0.24 %
|
| 12 Weeks |
6.11 %
|
3.48 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -13.70 %
|
|
EPS Growth in Last Year: 3.28 %
|
|
Sales Growth in Last Quarter: -3.24 %
|
|
Sales Growth in Last Quarter: 13.97 %
|
|
